Diabetes Therapeutic Market Reached $24.9 Billion in 2009
Summary
In some cases oral medication and/or insulin is prescribed, especially where diet or exercise is not enough, creating an opportunity for drug makers.“Diabetes is seen as kind of a ‘safe bet’ development area as pharmacos try to carve out a piece of this income stream with a treatment that is a bit more effective,” said Bruce Carlson, Publisher of Kalorama Information.Even if there were improvement, there would still be a large pool of existing patients requiring treatment.” Top companies in the market include NovoNordisk, Sanofi-Aventis, GlaxoSmithKline, Merck and Tekada.Major contributing factors to grow are increasing obesity and an aging worldwide population.“Diabetes is seen as kind of a ‘safe bet’ development area as pharmacos try to carve out a piece of this income stream with a treatment that is a bit more effective,” said Bruce Carlson, Publisher of Kalorama Information.Even if there were improvement, there would still be a large pool of existing patients requiring treatment.”Top companies in the market include NovoNordisk, Sanofi-Aventis, GlaxoSmithKline, Merck and Tekada.